Phosphoprotein 32 (PP32) is a tumor suppressor that can inhibit several types of cancers, including prostate and breast cancers. The protein encoded by this gene is one of at least two proteins that are similar in amino acid sequence to PP32 and are part of the same acidic nuclear phosphoprotein gene family. However, unlike PP32, the encoded protein is tumorigenic. The tumor suppressor function of PP32 has been localized to a 25 amino acid region that is divergent between PP32 and the protein encoded by this gene. This gene does not contain introns.[3]
↑Kadkol SS, Brody JR, Pevsner J, Bai J, Pasternack GR (March 1999). "Modulation of oncogenic potential by alternative gene use in human prostate cancer". Nature Medicine. 5 (3): 275–9. doi:10.1038/6488. PMID10086381.
↑Brody JR, Kadkol SS, Mahmoud MA, Rebel JM, Pasternack GR (July 1999). "Identification of sequences required for inhibition of oncogene-mediated transformation by pp32". The Journal of Biological Chemistry. 274 (29): 20053–5. doi:10.1074/jbc.274.29.20053. PMID10400610.
Matilla A, Radrizzani M (2005). "The Anp32 family of proteins containing leucine-rich repeats". Cerebellum. 4 (1): 7–18. doi:10.1080/14734220410019020. PMID15895553.
Kochevar GJ, Brody JR, Kadkol SS, Murphy KM, Pasternack GR (June 2004). "Identification of a functional mutation in pp32r1 (ANP32C)". Human Mutation. 23 (6): 546–51. doi:10.1002/humu.20030. PMID15146458.
Fan Z, Beresford PJ, Zhang D, Xu Z, Novina CD, Yoshida A, Pommier Y, Lieberman J (February 2003). "Cleaving the oxidative repair protein Ape1 enhances cell death mediated by granzyme A". Nature Immunology. 4 (2): 145–53. doi:10.1038/ni885. PMID12524539.
Kadkol SS, El Naga GA, Brody JR, Bai J, Gusev Y, Dooley WC, Pasternack GR (July 2001). "Expression of pp32 gene family members in breast cancer". Breast Cancer Research and Treatment. 68 (1): 65–73. doi:10.1023/A:1017919507109. PMID11678310.
Bai J, Brody JR, Kadkol SS, Pasternack GR (April 2001). "Tumor suppression and potentiation by manipulation of pp32 expression". Oncogene. 20 (17): 2153–60. doi:10.1038/sj.onc.1204294. PMID11360199.
Kadkol SS, Brody JR, Pevsner J, Bai J, Pasternack GR (September 1999). "Correction to "Modulation of oncogenic potential by alternative gene use in human prostate cancer"". Nature Medicine. 5 (9): 1087. doi:10.1038/12530. PMID10471270.